Tag: Stock pick

The Nextdc Ltd (ASX: NXT) share price is in focus after the company reported an 11% jump in contracted utilisation to 740MW, following new customer contract wins. The company’s forward order book has also risen, now standing at 565MW.

What did NEXTDC report?

• Contracted utilisation as at 30 June 2026 grew by 73MW (up 11%) to 740MW.
• Pro-forma forward order book increased to 565MW.
• Order book expected to convert to billings, revenue and EBITDA from FY26 to FY30.
• FY26 net revenue, underlying EBITDA and capex guidance remain unchanged.

What else do investors need to know?

NEXTDC attributes its contracted utilisation lift to recent customer contract wins, strengthening its position as a leading data centre platform for the digital economy. The company says its pro-forma forward order book, now at 565MW, will progressively convert to revenue streams over the coming years.

Importantly, NEXTDC confirmed that guidance for FY26 net revenue, underlying EBITDA and capital expenditure is unchanged from previous updates. This gives investors some predictability for near-term financial performance.

What’s next for NEXTDC?

NEXTDC intends to deliver on its strong contract pipeline, moving forward orders to revenue and earnings between FY26 and FY30. The stability in earnings guidance suggests management is confident in executing its growth plans.

With its expanding customer base and certified Tier IV operations, NEXTDC is well-placed to respond to continued demand for cloud and data centre services across Australia and Asia.

NextDC share price snapshot

The NextDC share price has underperformed the market over the past 12 months with a decline of almost 7%. This compares to a gain of almost 1.5% from the S&P/ASX 200 Index (ASX: XJO).

View Original Announcement

The post NEXTDC share price on watch as contracted utilisation rises and forward order book grows appeared first on The Motley Fool Australia.

More reading

• 3 top ASX 200 shares I’d buy for a self-managed superannuation fund
• Here are the top 10 ASX 200 shares today
• Which ASX tech companies does Macquarie like in the surging cloud computing sector?
• SK Hynix IPOs in the US. Here’s what that means for ASX investors
• 2 ASX shares tipped to grow 45% or more in the next 12 months

Motley Fool contributor James Mickleboro has positions in Nextdc. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Contact Energy Ltd (ASX: CEN) share price is on investors’ radar after the company posted higher electricity and gas sales for June 2026, along with ongoing progress on major renewable energy projects.

What did Contact Energy report?

• Mass market electricity and gas sales reached 495 GWh in June 2026, up from 410 GWh last year
• Contracted wholesale electricity sales totalled 1,056 GWh (June 2025: 810 GWh)
• Electricity and steam net revenue was $175.68/MWh, compared to $186.08/MWh in June 2025
• Electricity generated (or acquired) increased to 1,101 GWh (June 2025: 846 GWh)
• Unit generation cost, including acquired generation, dropped to $38.16/MWh from $54.27/MWh
• Retail netback decreased slightly, to $141.18/MWh from $146.32/MWh

What else do investors need to know?

Contact Energy is progressing with several renewable energy developments, including the Kōwhai Park Solar, Te Mihi Stage 2 geothermal, Glenbrook-Ohurua Battery 2, and Glorit Solar, with a combined approved cost of over $1.5 billion and staggered completion dates out to 2028.

Hydro storage levels were well above average as of mid-July 2026, with the South Island at 145% and the North Island at 123% of mean levels. The Clutha catchment saw strong inflows, supporting overall storage and generation options.

New Zealand’s electricity demand remained broadly steady, down 0.04% on June 2025, but up 1.1% versus June 2024, during what was the warmest June on record.

What’s next for Contact Energy?

Contact Energy is maintaining its focus on expanding renewable energy, reducing unit generation costs, and delivering reliable energy for customers. Upcoming project completions, especially in solar and battery storage, are poised to increase renewable supply in the next few years.

The company’s continued investments in sustainability, along with a healthy pipeline of projects, underline its commitment to low-carbon generation and growing market share in a stable demand environment.

Contact Energy share price snapshot

Over the past 12 months, Contact Energy shares have declined 6%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 1% over the same period.

View Original Announcement

This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The post Contact Energy June 2026 earnings: Sales rise, renewables progress appeared first on The Motley Fool Australia.

More reading

• HUB24 earnings: Record $18.9bn net inflows lift FUA
• Telix Pharmaceuticals: Q2 2026 revenue jumps 21%
• 5 things to watch on the ASX 200 on Tuesday
• Here are the top 10 ASX 200 shares today
• South32 reveals FY26 operating results

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus after the company posted Q2 2026 group revenue of US$247 million, up 21% on the prior year, and reaffirmed its full-year revenue guidance.

What did Telix Pharmaceuticals report?

• Q2 2026 group revenue: US$247 million, up 21% year-over-year and 7% quarter-on-quarter
• Precision Medicine revenue: US$202 million, up 30% year-over-year and 9% quarter-on-quarter
• TMS revenue: US$45 million
• FY 2026 revenue and other income expected to exceed US$1 billion, tracking towards the upper end of guidance (US$950–970 million plus US$40 million Regeneron income)
• R&D expenditure guidance updated to US$230–270 million, reflecting increased investment capacity
• Initial non-refundable payment of US$40 million received from strategic partner Regeneron

What else do investors need to know?

Telix Pharmaceuticals continues to make progress across both its Precision Medicine and Therapeutics businesses. The company achieved a key regulatory milestone for the global Phase 3 trial of TLX591-Tx in prostate cancer, with FDA alignment allowing the study to advance to Part 2 in the US. Enrolment is ongoing in several regions, including Australia and China.

In its Precision Medicine business, Telix is nearing full patient enrolment in the BiPASS Phase 3 study for initial prostate cancer diagnosis, and has completed enrolling for its Phase 3 registrational study in Japan for Illuccix. The company is also progressing new regulatory filings and expanding its manufacturing footprint with new facilities in Melbourne, Brussels, and Yokohama.

Telix finalised a major strategic collaboration with Regeneron to develop radiopharmaceutical therapies, receiving an upfront payment and creating a strong platform for future oncology programs. The company also refinanced existing convertible bonds, boosting its capital flexibility.

What did Telix Pharmaceuticals management say?

Dr. Christian Behrenbruch, Managing Director and Group CEO, said:

We delivered another quarter of growth with U.S. dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA imaging portfolio. This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix’s market leadership, built on clinical differentiation, supply chain resilience and commercial execution. During the quarter, we achieved key regulatory, commercial and clinical milestones across both our Precision Medicine and Therapeutics businesses. We are tracking in line with the upper end of our FY 2026 revenue guidance and are investing further in R&D to accelerate a number of high-value programs that have the potential to create significant future growth and shareholder value

What’s next for Telix Pharmaceuticals?

Looking ahead, Telix expects FY 2026 revenue and other income to top US$1 billion, and is allocating additional funds to R&D to support the expansion of key clinical programs. Progress in product development, regulatory filings, and the new Regeneron partnership are expected to underpin further growth.

Management flagged ongoing milestones for pivotal clinical trials in both the Therapeutics and Precision Medicine businesses, as well as continued global geographic expansion. The company’s strengthened capital position will support investment in its late-stage pipeline and manufacturing capability, with a focus on bringing new therapies to market.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix shares have declined 40%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 1% over the same period.

View Original Announcement

The post Telix Pharmaceuticals: Q2 2026 revenue jumps 21% appeared first on The Motley Fool Australia.

More reading

• HUB24 earnings: Record $18.9bn net inflows lift FUA
• Top 3 ASX healthcare stocks to watch
• Contact Energy June 2026 earnings: Sales rise, renewables progress
• 5 things to watch on the ASX 200 on Tuesday
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The ASX dividend share Future Generation Australia Ltd (ASX: FGX) could be one of the best choices that Aussie retirees could make. It offers numerous benefits to investors focused on passive income, as well as people who want diversification.

Future Generation Australia is a name I’ve had in my portfolio for several years already and I plan to continue holding it for a few different reasons.

Let’s look at why it’s such a compelling reason for retirees to buy for the long-term.

Diversification

Future Generation Australia is a listed investment company (LIC) that is invested in the funds of fund managers like Paradice, L1 Group Ltd (ASX: L1G), Wilson Asset Management, Vinva, Eley Griffiths and so on.

All of those find managers work for free so that Future Generation Australia can donate 1% of its net assets each year to youth charities, including Giant Steps, Mirabel Foundation, Raise, Karinyahouse and Lighthouse.

By being invested in so many different fund managers, the ASX dividend share gives investors exposure to more than 430 businesses.

I think it really ticks the diversification box, while also giving more market capitalisation diversification.

Around 19% of the portfolio is invested in companies outside of the S&P/ASX 300 Index (ASX: XKO), showing that the LIC can give exposure to some of the smaller and more growth-orientated stocks in Australia – I think this is a key reason why Future Generation Australia’s portfolio has beaten the return of the S&P/ASX All Ordinaries Accumulation Index (ASX: XAOA) by an average of around 1% per year.

Large dividend yield

One of the main reasons to like this ASX dividend share is its strong dividend yield. There are few businesses that I’d be more willing to invest in for a large dividend yield than Future Generation Australia.

The business expects to pay an annual dividend per share for 2026 of 7.6 cents. At the time of writing, that translates into a grossed-up dividend yield of 8%, including franking credits.

In my view, that’s a far better yield than what term deposits and most other ASX blue-chip shares have to offer.

Growing payouts

Another reason for retirees to love this business is that it has regularly increased its annual dividend for investors. It has increased its annual payout each year since 2015, so 2026 is more than a decade of increases.

Dividend growth is not guaranteed, of course, but with Future Generation Australia’s impressive track record and profit reserve of 41.8 cents per share, I think it’s well positioned to continue growing dividends in the next few years.

Over the long-term, I think Future Generation Australia can continue to deliver rising payouts for retirees and other shareholders.

The post Why this ASX dividend share is a retiree’s dream for 2026 appeared first on The Motley Fool Australia.

More reading

• How much is needed in superannuation to target a $100,000 annual passive income?
• How much superannuation is needed to target a $100,000 annual passive income?
• 2 ASX shares with dividend yields above 7.5%
• How much is needed in superannuation to target $60,000 in annual passive income?
• $1,000 buys 735 shares in an incredibly reliable ASX dividend stock

Motley Fool contributor Tristan Harrison has positions in Future Generation Australia. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Westpac Banking Corp (ASX: WBC) shares usually come with a pleasing level of passive income, more than what someone could get from a term deposit.

It’s a good idea to remember that Westpac wants to keep shareholders happy, so dividends are likely to keep flowing unless something goes really wrong, like we saw at the start of 2020.

Westpac is one of the leading ASX bank shares, along with names like Commonwealth Bank of Australia (ASX: CBA), National Australia Bank Ltd (ASX: NAB), Macquarie Group Ltd (ASX: MQG) and ANZ Group Holdings Ltd (ASX: ANZ).

By owning enough Westpac shares, an investor could generate $1,000 of passive income, or even more.

What would it take to create $1,000 of passive income?

Westpac’s dividends have been stable (with a little bit of growth) over the last couple of years. I think it’s likely the ASX bank share will aim to continue gradually increasing its payouts in the coming years.

According to Commsec’s projections, Westpac is forecast to slightly increase its annual payout in FY27 to $1.55 per share. That translates into a grossed-up dividend yield of 6.1% with franking credits and 4.2% without.

If an investor wanted to receive $1,000 of dividend income, it’d take 646 Westpac shares. If we include the franking credits as part of the income, it’d take 452 Westpac shares to generate that level of income based on the projected payout for FY26.

At the time of writing, that means an investor would need to invest approximately $23,600 or $16,500, depending on whether franking credits are included.

Is this a good time to invest in Westpac shares?

Analysts are not convinced that the Westpac share price is good value, despite the fact that it’s down more than 10% since the 2026 high in April 2026.

According to CMC Invest, there have been eight analyst ratings on the ASX bank share within the last three months, with three of them being holds and five of them being sells. In other words, not a single buy recommendation among them.

The average price target from those analysts is $32.84, implying a possible decline of 10% from where it is at the time of writing. Therefore, the ASX bank share may not be a great investment to consider today.

According to the projection on CMC Invest, the Westpac share price is now valued at around 18x FY26’s estimated earnings, at the time of writing.

The post How much must I invest in Westpac shares to earn a $1,000 passive income in 2027? appeared first on The Motley Fool Australia.

More reading

• Are Westpac shares a top buy this week?
• If I invest $10,000 in Westpac shares, how much passive income will I receive in 2027?
• What are experts tipping for the big four bank shares in the back half of 2026?
• How much passive income can I earn off a $50,000 portfolio?
• ANZ, NAB, Westpac and CBA shares: Brokers rate 2 a sell, and 2 a hold

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) and Telstra Group Ltd (ASX: TLS) shares offer investors two very different paths.

One is working through a difficult reset, while the other continues to deliver the steadier performance investors expect from a defensive blue chip.

If I could buy only one today, which would I choose?

The case for Telstra shares

I can see plenty to like about Telstra.

Connectivity has become essential to how Australians work, communicate, shop, travel, and access entertainment. That gives the company a level of demand that many businesses would love to have.

Its mobile division remains the main attraction for me. Telstra has continued growing mobile revenue as customers choose its network and accept higher prices, while cost reductions have also supported earnings.

I also value the income profile. Telstra has been growing its dividend, and its cash flow gives investors a degree of stability that CSL cannot currently match.

The trade-off is the valuation. At a share price of around $5.07, Telstra trades on a price-to-earnings ratio of approximately 25.6 times estimated FY26 earnings of 19.8 cents per share. The multiple remains around 25.4 times based on the FY27 consensus estimate of 20 cents.

That feels quite full when consensus forecasts suggest very little earnings growth between those years.

Why CSL shares look more compelling

CSL shares are trading around $122.61, compared with consensus earnings estimates of $8.22 per share in FY26 and $8.36 in FY27.

That places the biotechnology company on price-to-earnings ratios of approximately 14.9 times and 14.7 times, respectively.

Their sectors and earnings profiles are different, so those multiples need context. But even with that caveat, the gap is hard to ignore.

CSL is cheaper because confidence has collapsed.

Management has reduced its outlook, the Vifor acquisition has underperformed, and growth initiatives are taking longer to improve the financial results. The company has also faced challenges involving US immunoglobulin inventories, albumin pricing in China, research productivity, a change of CEO, and operating complexity.

Those problems could continue testing shareholders. However, the current valuation appears to reflect a deeply pessimistic view of what comes next.

CSL still owns a global plasma collection and manufacturing network that has taken decades to build. Demand for immunoglobulin therapies continues to grow, while large numbers of potential patients remain undiagnosed or untreated.

Management is also simplifying the organisation, improving plasma and manufacturing efficiency, and targeting substantial annual savings by FY28.

The recovery may take time, but I don’t think CSL needs to return immediately to its former market valuation for shareholders to do well from here. Better execution and a return to dependable earnings growth could be enough to change sentiment considerably and support a re-rating.

Which share would I buy?

Telstra would be my choice for an investor who prioritises defensive earnings and dividends.

For my own portfolio, I would buy CSL shares.

The biotech carries greater uncertainty, and another disappointment could send the share price lower. In return for accepting that risk, investors are being offered a much cheaper valuation and what I believe is considerably more upside if conditions improve.

Foolish takeaway

Telstra is doing many of the things shareholders would want to see, but its valuation already gives the company credit for that steadiness.

CSL is being priced as though its recent problems will weigh on the business for years. That could happen, although I think the strength of its core operations gives it a credible route back to growth.

I would be happy to own both shares. But choosing just one at current prices, I think CSL offers the more compelling balance between risk and potential reward.

The post CSL vs Telstra shares, which should I buy? appeared first on The Motley Fool Australia.

More reading

• I’d listen to Warren Buffett and buy cheap ASX shares
• How to build an ASX dividend portfolio that keeps paying you for decades
• Down 50%+: Are these ASX healthcare shares finally worth buying?
• Could CSL shares double from here? Here’s what the experts think
• How much is needed in superannuation to target a $100,000 annual passive income?

Motley Fool contributor Grace Alvino has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The BHP Group Ltd (ASX: BHP) share price has dropped more than 10% since mid-June, as the chart below shows, which has boosted the dividend yield.

BHP has been an excellent dividend pick over the last decade, with the ASX mining share benefiting from various times of higher iron ore prices. Even an iron ore price of US$100 per tonne can allow it to make good earnings.

The company’s main commodities are iron ore and copper, though it also produces coal and is building a potash project in Canada called Jansen.

Following the company’s recent valuation decline, I think it’s worthwhile to consider the ASX mining share.

Dividend projection

According to the forecast on Commsec, the business could deliver a relatively pleasing dividend payout for shareholders.

The business is projected to pay an annual dividend per share of A$2.148 in the 2026 financial year. At the time of writing, this translates into a forward grossed-up dividend yield of 5.4%, including franking credits.

That’s not the biggest dividend yield on the ASX and the BHP dividend yield has been higher in recent years. That’s partly because the BHP share price has gone up so much in recent times, it’s (still) up 25% this year and up 47% in the past 12 months.

The higher the share price goes, the lower the dividend yield, assuming the dividend payment stays the same.

Is the BHP share price a buy?

There’s much more to the appeal of a business than just the passive income on offer.

The valuation also needs to make sense; otherwise, capital losses could offset the passive dividend income.

The latest update from the ASX mining share was its operating update for the period ending 30 June 2026.

Its most important commodities are iron ore and copper, so I’ll focus on those.

In the three months to June 2026, copper production was 491.9k, up 3% quarter-over-quarter but down 5% year-over-year. Iron ore production was 68.1mt, up 8% quarter-over-quarter, but down 3% year-over-year.

What was perhaps even more interesting was the guidance it gave. BHP produced 1.95mt of copper in FY26, but only expects between 1.65mt to 1.8mt of copper in FY28 – a sizeable decline. FY27 iron ore production is expected to be between 260mt to 272mt, down from 264.7mt in FY26.

Lower copper production is not ideal, given its plans to ramp up production in the coming years to take advantage of strong demand.

Even so, both the copper price and iron ore price are at strong enough levels that the business can generate strong profits. However, at the current elevated BHP share price, I’m not sure it’s an attractive buy.

Broker analysts seem to have a similar view. According to CMC Invest, of 14 recent ratings on the ASX mining share, two were buys and 12 were holds. The average price target is $59.08, suggesting only a slight rise (at the time of writing) over the next 12 months.

There are quite a few other ASX shares I’d rather buy for dividends.

The post Is the BHP share price a buy for its 5% dividend yield? appeared first on The Motley Fool Australia.

More reading

• BHP shares soared 62% in FY26. Can they keep climbing?
• Why I think BHP is the best ASX mining share
• How to build an ASX dividend portfolio that keeps paying you for decades
• What is Morgan’s updated view on Rio Tinto and BHP shares?
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

BHP shares were one of the standout performers on the ASX 200 last financial year.

The BHP share price soared 62% in FY26 to finish at $59.40 on 30 June.

That was a spectacular run for the Australia’s largest company.

The question now is whether the shares can keep climbing in FY27.

Let’s take a look.

What drove BHP shares higher in FY26

Two forces did most of the heavy lifting.

First, commodity prices ran hot: the copper price rose 18% over FY26 and hit a record US$6.60 per pound in May.

Iron ore prices also climbed by around 7%.

Second, investors rotated heavily into mining stocks.

That combination pushed BHP shares to a new high in FY26.

Yet there is a bigger story here: BHP is now the world’s largest copper producer.

Copper made up more than half of the company’s underlying EBITDA in the first half of FY26. Copper is essential to electrification, data centres, and the broader energy transition. All of these are global megatrends that can be expected to only intensify in future years.

For the first time in BHP’s history, copper earnings exceeded those of iron ore.

Can BHP shares keep climbing?

After such a big run, the easy gains may be behind us.

Most brokers are now sitting on the fence.

Morgans recently reiterated a hold rating and lifted its target from $54.90 to $59.80. Macquarie also has a hold rating with a $60.20 target. Overall, the broker consensus target sits near $61.44.

Based on recent prices, that implies only modest single-digit upside.

The dividend still appeals, though. CommSec estimates dividends of $2.10 per share in FY26, a yield of around 3.6%.

BHP’s balance sheet also remains strong, with low net debt.

However, not everything is smooth sailing. A review of the Jansen potash project in Canada resulted in a hefty cost blowout.

There is also the ongoing concern around industrial action at BHP’s Pilbara iron ore operations.

Investors will get more clarity when the company reports its FY26 results on 18 August.

Foolish takeaway

BHP shares have had a brilliant run.

Copper’s growing role in the global economy also gives investors a long-term tailwind.

But after a 62% gain, brokers see only limited near-term upside.

For patient investors, the dividend and copper leverage may still appeal.

Just don’t expect BHP shares to repeat their FY26 heroics every single year.

The post BHP shares soared 62% in FY26. Can they keep climbing? appeared first on The Motley Fool Australia.

More reading

• Why I think BHP is the best ASX mining share
• How to build an ASX dividend portfolio that keeps paying you for decades
• What is Morgan’s updated view on Rio Tinto and BHP shares?
• 5 things to watch on the ASX 200 on Monday
• Buy, hold, sell: BHP, CBA, and Rio Tinto shares

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

I think the best way to invest in ASX shares is for the long-term, with a decade or more being my preferred investment time horizon.

If investors hold for that length of time, it gives compounding the best opportunity to deliver results over the long-term.

Given how rapidly the world is changing in relation to technology and AI, I’m less optimistic about some ASX tech stocks than I used to be. That’s partly why I think the investments below could be strong ASX share picks for the long term.

Guzman Y Gomez Ltd (ASX: GYG)

GYG is one of the best quick service restaurant (QSR) businesses in Australia, in my view. At the end of March 2026, it had 242 Australian locations, along with 23 Singapore restaurants and five Japanese locations.

The company is aiming for 1,000 Australian restaurants within the next 20 years, which could mean significant network sales growth and excellent scale benefits.

In the third quarter of FY26, the company reported that Australian total network sales rose by 19.7% to $320.4 million, and Asian network sales grew by 15% to $21.5 million.

The business is growing network sales thanks to both solid comparable sales growth and an expanding mutlinational network.

Over the next decade, I expect the company to significantly increase its restaurant network, increase its market awareness and boost profit margins. I believe the market is underestimating how much the business could grow network sales overseas, which could unlock a lot of royalty income – its Asian operations are under a master franchise agreement.

According to the company, it’s expecting its Australian and Asian operations to grow their underlying operating profit (EBITDA) by 29% in FY26 to $85 million, showing an increase in its profit margins.

According to the projection on Commsec, the GYG share price is valued at 33x FY28’s estimated earnings, which I think is an appealing price for this fast-growing ASX share.

Global X S&P World Ex Australia GARP ETF (ASX: GARP)

Another investment that I want to highlight is this exchange-traded fund (ETF), which aims to give investors exposure to a portfolio of global businesses that fit the bill when it comes to the investing strategy ‘growth at a reasonable price’ (GARP).

When you buy growing businesses at a good price, it can lead to excellent investment returns over the long-term.

There are three different things that the GARP ETF looks for to include in its portfolio of 250 companies across different countries and sectors.

It wants to see growth characteristics, with a good pace of 3-year sales and earnings growth.

Second, it wants to see ‘value’. That is identified by the price/earnings (P/E) ratio.

Finally, this GARP strategy involves looking at the quality of these businesses. That includes looking at the financial leverage (debt levels) and return on equity (ROE). ROE tells us how much profit is making compared to the retained amount of shareholder money – the higher the ROE the better.

Since inception in September 2024, the GARP ETF has returned an average of 16.8%. Past performance is not a guarantee of future returns of course, but I’m bullish about this strategy being able to continue to deliver good returns for the next decade and beyond.

These aren’t the only ASX shares I think would make excellent long-term investments.

The post 2 top ASX shares to buy and hold for the next decade appeared first on The Motley Fool Australia.

More reading

• Own ACDC, FANG, or SEMI ETF? Global X is paying your dividend today!
• A rare buying opportunity in 1 of Australia’s top shares?
• Where I’d invest $20,000 into ASX growth shares right now
• 2 ASX shares highly recommended to buy: Experts
• The currency-hedged ASX ETFs magnifying dividends by up to 10x this season

Motley Fool contributor Tristan Harrison has positions in Guzman Y Gomez. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Fortunately for income investors, there are lots of ASX dividend shares to choose from.

But with so much choice, it can be hard to decide which ones to buy.

To narrow things down, let’s look at three dividend shares with 5%+ dividend yields that analysts are tipping as buys.

They are as follows:

Charter Hall Long WALE REIT (ASX: CLW)

The team at Citi thinks that Charter Hall Long WALE REIT could be a top pick for income investors.

The broker has a buy rating and $4.10 price target on the long-lease focused property company’s shares.

Citi highlights that the company’s shares offer value at current levels, especially with a large portion of rents inflation-linked and its big dividend yield.

Speaking of which, the broker is forecasting dividends per share of 25.5 cents in FY 2026 and then 25.7 cents in FY 2027. Based on its current share price of $3.71, this would mean dividend yields of approximately 6.9% in both years. 

Harvey Norman Holdings Ltd (ASX: HVN)

Another ASX dividend share that could be worth considering is retail giant Harvey Norman.

Bell Potter is bullish on the company and has a buy rating and $6.00 price target on its shares.

Although the broker expects FY 2027 to be a tough year, it believes this is more than priced in. So, with generous dividend yields expected, it sees now as a good time to snap up Harvey Norman’s shares. 

Bell Potter is forecasting fully franked dividends of 31.1 cents per share in FY 2027 and then 33.3 cents per share in FY 2028. Based on its current share price of $4.82, this equates to dividend yields of 6.5% and 6.9%, respectively.

Universal Store Holdings Ltd (ASX: UNI)

A third ASX dividend share that brokers are recommending to clients is Universal Store. 

Morgans has a buy rating and $9.50 price target on the youth fashion retailer’s shares.

The broker has been pleased with the company’s performance in FY 2026, highlighting that double-digit sales growth is expected despite tough operating conditions.

It notes that Universal Store’s Perfect Stranger brand is performing strongly, which bodes well for its store rollout. 

With respect to income, Morgans is forecasting the company to pay fully franked dividends of 40 cents per share in FY 2026 and then 46 cents per share in FY 2027. Based on its current share price of $7.43, this represents dividend yields of 5.4% and 6.2%, respectively.

The post 3 ASX dividend shares to buy with 5%+ yields appeared first on The Motley Fool Australia.

More reading

• How much is needed in superannuation to target a $100,000 annual passive income?
• Top brokers name 3 ASX shares to buy next week
• 2 ASX dividend shares with yields above 7%
• How much do I need in my superannuation to earn an annual $60,000 passive income?
• Brokers name 2 ASX dividend shares to buy with 4% to 7% yields

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has positions in Universal Store. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Harvey Norman. The Motley Fool Australia has recommended Universal Store. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.